Table 7 Univariate sensitivity analysis parameters and ranges
Univariate Sensitivity Parameter | Min | Max |
|---|---|---|
Discount rate (baseline = 3% for costs, 3% for benefits) | 0% | 6% |
All costs (excluding chemotherapy drugs) varied by ± 25% (baseline = 100%) | 75% | 125% |
Chemotherapy drugs varied by ± 25% (baseline = 100%) | 75% | 125% |
All costs varied by +/- 25% (baseline = 100%) | 75% | 125% |
Per vial costing with 100 mg and 500 mg pemetrexed vials available | - | - |
Mean body surface area (BSA) in m2 | 1.6 | 2 |
Chemotherapy administration time varied +/- 50% (baseline = 100%) | 50% | 150% |
Hospital days for AE varied +/- 50% (baseline = 100%) | 50% | 150% |
Exclude BSC costs for treated patients once they complete treatment or enter progression | - | - |
Cost of febrile neutropenia varied by +/- 25% (baseline = 100%) | € 2483 | €4139 |
Disutility assigned to AEs varied +/- 50% (baseline = 100%) | 50% | 150% |
Assume no disutility assigned to AEs (so only have a cost impact in model) | - | - |
Utility weights assigned to health states varied between upper and lower 95% CI | 0.60 stable/response 0.50with an AE | 0.72stable/response 0.66with an AE |
95% CI for response rate for PEM (base case = 10.78%) | 7.25% | 15.80% |
95% CI for response rate for DOC (base case = 8.81%) | 5.59% | 13.66% |
95% CI for survival hazard ratio for PEM vs. DOC (base case = 0.778) | 0.607 | 0.997 |
95% CI for progression free survival hazard ratio for PEM vs. DOC (base case = 0.823) | 0.664 | 1.020 |
Assume weighted terminal/palliative care cost | €6927 | - |
Model time horizon set to 1 year (baseline = 3 years) | - | - |
Setting cost of fatigue to zero | - | - |
Duration of treatment (no. of cycles; base case = 6) | 4 | 5 |